Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-22
2007-05-22
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S112000, C546S152000, C546S159000, C514S311000, C514S314000
Reexamination Certificate
active
10688566
ABSTRACT:
The invetion relates to compounds of formula (I)wherein R1, R2, R3, R4, R5, R6, R7and R8are as defined in the description, their use as medicament, pharmaceutical compositions containing them and processes for their preparation.
REFERENCES:
patent: 4521607 (1985-06-01), Oka et al.
patent: 5753677 (1998-05-01), Ogawa et al.
patent: 6140342 (2000-10-01), Goldstein et al.
patent: 6140343 (2000-10-01), DeNinno et al.
patent: 6147089 (2000-11-01), DeNinno et al.
patent: 6147090 (2000-11-01), DeNinno et al.
patent: 6197786 (2001-03-01), DeNinno et al.
patent: 6310075 (2001-10-01), DeNinno et al.
patent: 6362198 (2002-03-01), Goldstein et al.
patent: 6395751 (2002-05-01), DeNinno et al.
patent: 6489478 (2002-12-01), DeNinno et al.
patent: 6586448 (2003-07-01), DeNinno et al.
patent: 6906082 (2005-06-01), DeNinno et al.
patent: 2004/0082609 (2004-04-01), Ghosh et al.
patent: 2005/0038070 (2005-02-01), Inman et al.
patent: 2005/0228016 (2005-10-01), Michelotti et al.
patent: 2006/0063803 (2006-03-01), Ruggeri et al.
patent: 0987251 (2000-03-01), None
patent: 1170594 (2002-01-01), None
patent: 200253557 (2002-02-01), None
patent: WO 9105549 (1991-05-01), None
patent: WO 0017165 (2000-03-01), None
patent: WO 02079165 (2002-10-01), None
patent: WO2004052863 (2004-06-01), None
Hiroyuki Abe, et al, Gene, 227, 1999, pp. 71-77.
Kinya Nagata, et al, FEBS Letters, 459, 1999, pp. 195-199.
XP 002244840, Zhumal Obschchei Khimii, 1963, 33(6), p. 1956-1958.
XP 002244841, MCL Screening Compounds, May 24, 2001, Accession #2001:10000970 CHEMCATS.
XP 002244842, Scientific Exchange Product Line, Accession # 2003:294034 CHEMCATS, Jan. 2003.
XP 002244843, Enamine Product Listing, Accession #2000:1095101 CHEMCATS, Nov. 15, 2001.
XP 002244839, 1966, No. 4, p. 5-16, Trudy Problemnio Laboratoirii Khimii Vysokomolekulyamykh Soedinenii.
XP 002244845, Vitas-M Screening Collection, Accession #2002:304333 CHEMCATS, Mar. 22, 2001.
XP 002244844, MicroChemistry Screening Collection, Accession #2001:2763118 CHEMCATS, Oct. 3.
XP 002244846, ChemBridge Product List, Accession #2002:601263 CHEMCATS, Jan. 17, 2002.
XP 002244847, Interchim Intermediates, Accession # 2002:2633209 CHEMCATS, Jul. 9.
U.S. Appl. No. 10/807,838, filed Mar. 23, 2004 (our reference:PC25623A).
U.S. Appl. No. 60/612,863, filed Sep. 23, 2004 (our reference:PC32562).
U.S. Appl. No. 60/612,729, filed Sep. 23, 2004 (our reference:PC32416).
English Translation of WO 2004/052863.
Awad Mohamed M. Ali
Bazin Marc J.
Feru Frederic
Goldstein Steven W.
Kuhn Cyrille F.
Benson Gregg C.
Pfizer Inc.
Samuels Lisa A.
LandOfFree
Quinoline derivatives as CRTH2 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline derivatives as CRTH2 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives as CRTH2 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3822405